Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Confirmatory Clinical Trial to Evaluate the Efficacy and Safety of Ibritumomab Tiuxetan Injection (ZEVALIN)

Next Previous
X
Search
Trial Profile

A Confirmatory Clinical Trial to Evaluate the Efficacy and Safety of Ibritumomab Tiuxetan Injection (ZEVALIN)

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 18 Mar 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ibritumomab tiuxetan (Primary)
  • Indications Follicular lymphoma; Non-Hodgkin's lymphoma
  • Focus Registrational; Therapeutic Use
  • Sponsors CASI Pharmaceuticals

    • Most Recent Events

    • 16 Mar 2020 According to the CASI Pharmaceuticals media release, company expects this study to be initiated by early 2021.
    • 19 Feb 2019 According to a CASI Pharmaceuticals media release, the Company currently is addressing certain requirements provided by the Center for Drug Evaluation (CDE), a part of the NMPA, upon satisfying those requirements, the Company will start the ZEVALIN clinical development program in China.
    • 19 Feb 2019 According to a CASI Pharmaceuticals media release, the National Medical Products Administration (NMPA) has approved the Company's Clinical Trial Application (CTA) to allow for a confirmatory clinical trial to evaluate the efficacy and safety of ZEVALIN.The Company previously acquired greater China rights to ZEVALIN from Spectrum and intends to launch ZEVALIN in China as soon as the confirmatory trial is completed and marketing approval is received from the NMPA.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top